Despite the impact of COVID-19, the global Hepatitis B Diagnostic Tests Market grew at a healthy year-on-year (YoY) rate, reaching a valuation of approximately US$ 872.5 million in 2022. With the global prevalence of hepatitis B increasing, the overall market is expected to grow at a 6.4% CAGR between 2022 and 2028, surpassing a valuation of US$ 1.26 million by the end of 2028.
Request a Sample Report with Table of Contents and Figures@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1332
High Prevalence of Hepatitis B in the APEJ Region Boosting Global Market Revenue Growth
The APEJ region has the highest prevalence of hepatitis B, and the disease burden caused by chronic cases of hepatitis B is enormous. The APEJ region has the most chronic hepatitis B patients of any region in the world, making it a potential market for hepatitis B test kit manufacturers. According to WHO data, China accounts for one-third of all chronic hepatitis B infections. Furthermore, 6.2% of the adult population in the Western Pacific region has hepatitis B. Hepatitis B infects approximately 2% of the general population in South-East Asia. According to Hepatitis Australia, approximately 225,000 people are living with chronic hepatitis B in the country. As per the data provided by WHO, in India, the prevalence of hepatitis B surface antigen is 3%-4.2% with over 40 million hepatitis B carriers. Due to such high prevalence of hepatitis B in the Asia Pacific Excluding Japan region, the market for hepatitis B diagnostic tests has a huge potential in the region.
Global Hepatitis B Diagnostic Tests Market: Segmentation and Forecast
The global hepatitis B diagnostic tests market is segmented on the basis of product type, end user and region.
- Based on product type, the enzyme immunoassay kits segment was estimated to be worth nearly US$ 590 million in 2017 and is expected to be worth nearly US$ 1,100 million in 2027, representing a CAGR of 6.2% from 2017 to 2027.
- The hospitals segment was estimated to be valued at nearly US$ 250 million in 2017 and is expected to reach a valuation of nearly US$ 460 million in 2027, registering a CAGR of 6.1% during the assessment period.
- By region, the APEJ hepatitis B diagnostic tests market was estimated to be worth nearly US$ 200 million in 2017 and is expected to be worth nearly US$ 380 million by 2027, representing a 7.2% CAGR during the forecast period.
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-1332
Global Hepatitis B Diagnostic Tests Market: Competitive Landscape
This report features some of the important players functioning in the global hepatitis B diagnostic tests market such as bioMérieux SA, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., Abbott Laboratories, Meridian Bioscience, Inc., Vista Diagnostics International, Biogate Laboratories Ltd., J.Mitra & Co. Ltd., Siemens Medical Solutions USA, Inc. and General Biologicals Corporation.
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs